Peanut Allergy Treatment Market Size - Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The peanut allergy treatment market encompasses pharmaceutical and immunotherapy-based products designed to reduce or manage immune system reactions to peanut proteins, the most common and potentially severe food allergen worldwide. Estimated at roughly half a billion dollars in 2025, the market sits at an early but accelerating stage of commercialization following landmark regulatory approvals of oral immunotherapy treatments in major markets. Growth is being propelled by a combination of increasing clinical awareness, expanding patient diagnosis, and the transition from strictly avoidance-based management toward active treatment protocols.

• •Market size estimated at approximately $530-537 million across major Western and Asian markets in 2024-2025
• •Peanut allergy represents the largest share of the broader food allergy treatment market, estimated at over 20% of a multi-billion-dollar sector
• •FDA-approved oral immunotherapy products have shifted the market from pure avoidance strategies to active treatment options

Rising prevalence of peanut allergies, particularly among children in industrialized nations, is expanding the addressable patient population and fueling demand for approved therapies. Greater clinical recognition and more widespread diagnostic testing have increased the number of formally diagnosed patients seeking treatment beyond simple avoidance. Advances in immunotherapy and biologic drug development, alongside supportive regulatory pathways for orphan-designated allergy products, have encouraged pharmaceutical investment in the space.

• •Increasing peanut allergy prevalence in pediatric populations across North America, Europe, and parts of Asia-Pacific
• •FDA approval of oral immunotherapy products (such as peanut oral immunotherapy capsules) has created a billable treatment category where none existed before
• •Growing emphasis on desensitization therapies and biologics targeting immune pathways associated with food allergies

North America dominates the market, accounting for the largest share due to high disease prevalence, established regulatory pathways, and early adoption of approved therapies. Europe follows as the second-largest regional market, with growing clinical adoption supported by regulatory frameworks in the UK and several EU member states. The Asia-Pacific region represents a significant emerging opportunity driven by rising allergy diagnosis rates and increasing healthcare access, though market penetration remains lower than in Western markets.

• •North America holds the largest regional share, supported by FDA-approved treatments and high peanut allergy prevalence among children
• •Europe is the second-largest market, with the UK showing notable clinical uptake following regulatory endorsement of peanut immunotherapy
• •Asia-Pacific is an emerging growth region, with rising diagnostic rates and expanding access to specialty allergy care

What are the recent trends and outlook?

The market is expected to sustain strong growth through 2030 and beyond as additional therapies advance through clinical trials and regulatory agencies consider new product approvals. Biologic treatments targeting broader immune pathways represent a significant pipeline opportunity that could diversify the competitive landscape beyond oral immunotherapy. Wider insurance reimbursement, expanded clinical guidelines supporting immunotherapy as a standard care option, and potential geographic expansion of approved therapies are all expected to accelerate market adoption globally.

• •Pipeline development of biologic and monoclonal antibody therapies targeting immune pathways involved in food allergies
• •Potential for expanded labeling and age-range approvals for existing oral immunotherapy products to reach younger and larger patient populations
• •Growing integration of peanut desensitization into clinical practice guidelines, supporting broader adoption by allergists and healthcare providers